ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc (BMRN)

57,445
0,895
( 1,58% )
Mis à jour : 19:01:22

BioMarin Pharmaceutical Inc (BMRN) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
57,445
( 1,58% )
Prix Achat
57,41
Prix Vente
57,48
Volume échangé
1 162 406
56,85 Fourchette du Jour 57,855
49,2592 Plage de 52 semaines 66,275
Cap du marché
Clôture Veille
56,55
Ouverture
57,41
Dernière Transaction
10
@
57.45
Dernière heure de transaction
19:01:22
Volume financier
US$ 66 681 290
VWAP
57,3649
Volume moyen (3 m)
US$ 2 037 254
Actions en circulation
193 284 438
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
40,65
Bénéfice par action (BPA)
1,4
Chiffre d'affairess (LTM)
3,24B
Bénéfice net (LTM)
268,74M

À propos de BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products i... BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California. Show more

Secteur
Healthcare
Industrie
Biotechnology & Life Sciences
Site Web
Siège social
San Rafael, United States
Fondé
1996
BioMarin Pharmaceutical Inc est coté dans le secteur Healthcare de la NASDAQ avec le ticker BMRN. Le dernier cours de clôture d'BioMarin Pharmaceutical était de US$56,55. Au cours de la dernière année, les actions de BioMarin Pharmaceutical ont été négociées dans une fourchette de prix de US$ 49,2592 à US$ 66,275.

BioMarin Pharmaceutical compte actuellement 193 284 438 actions en circulation. La capitalisation boursière d'BioMarin Pharmaceutical est de US$11,10 milliard. BioMarin Pharmaceutical a un ratio cours/bénéfice (ratio PE) de 40.65.

Flux d'options BioMarin Pharmaceutical (BMRN)

Flux global

Haussier

Prime nette

109k

Calls / Puts

100,00%

Ach. / Vent.

0,00%

OTM / ITM

100,00%

Sweeps Ratio

0,00%

BMRN Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
13.3556.2026252542154.0957.85553.01226985455.43020227CS
44.5158.5301341394352.9357.85549.2592249216453.74039287CS
12-0.245-0.42468365401357.6958.3849.2592200074454.37884493CS
264.0957.6757263355253.3566.27549.2592218551056.91377094CS
520.5350.9400808293856.9166.27549.2592228434956.23085884CS
156-34.685-37.647888852792.1399.5649.2592189478569.57667846CS
260-22.015-27.705763906479.46117.7749.2592164353475.38885409CS

BMRN - Frequently Asked Questions (FAQ)

What is the current BioMarin Pharmaceutical Inc share price?
The current share price of BioMarin Pharmaceutical Inc is US$ 57,445
How many BioMarin Pharmaceutical Inc shares are in issue?
BioMarin Pharmaceutical Inc has 193 284 438 shares in issue
What is the market cap of BioMarin Pharmaceutical Inc?
The market capitalisation of BioMarin Pharmaceutical Inc is USD 11,1B
What is the 1 year trading range for BioMarin Pharmaceutical Inc share price?
BioMarin Pharmaceutical Inc has traded in the range of US$ 49,2592 to US$ 66,275 during the past year
What is the PE ratio of BioMarin Pharmaceutical Inc?
The price to earnings ratio of BioMarin Pharmaceutical Inc is 40,65
What is the cash to sales ratio of BioMarin Pharmaceutical Inc?
The cash to sales ratio of BioMarin Pharmaceutical Inc is 3,38
What is the registered address of BioMarin Pharmaceutical Inc?
The registered address for BioMarin Pharmaceutical Inc is 770 Lindaro Street, San Rafael, California, 94901
What is the BioMarin Pharmaceutical Inc website address?
The website address for BioMarin Pharmaceutical Inc is www.biomarin.com
Which industry sector does BioMarin Pharmaceutical Inc operate in?
BioMarin Pharmaceutical Inc operates in the Biotechnology & Life Sciences sector

BMRN Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock